Publications
Detailed Information
Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Chang Wook | - |
dc.contributor.author | Lim, Dae Jung | - |
dc.contributor.author | Son, Hwancheol | - |
dc.contributor.author | Lee, Sang Eun | - |
dc.contributor.author | Jeong, Hyeon | - |
dc.date.accessioned | 2010-06-28T23:12:28Z | - |
dc.date.available | 2010-06-28T23:12:28Z | - |
dc.date.issued | 2008-03-26 | - |
dc.identifier.citation | Urol Int. 2008;80(2):157-161 | en |
dc.identifier.issn | 1423-0399 (Electronic) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18362485 | - |
dc.identifier.uri | http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000112606&Ausgabe=234231&ProduktNr=224282&filename=000112606.pdf | - |
dc.identifier.uri | https://hdl.handle.net/10371/67950 | - |
dc.description.abstract | INTRODUCTION: We performed a prospective, randomized study to examine the efficacies of levofloxacin and doxazosin alone and as a combination therapy in patients with National Institutes of Health (NIH) category III chronic prostatitis/chronic pelvic pain syndrome. PATIENTS AND METHODS: Men with a NIH diagnosis of category III chronic prostatitis/chronic pelvic pain syndrome and who had experienced pelvic pain for more than 3 months during the last 6 months were enrolled. All patients underwent treatment for 6 weeks. The patients were assessed at baseline and after 2 and 6 weeks by using the NIH Chronic Prostatitis Symptom Index. Eighty-one men (average age 40.1 years) were randomized to either the levofloxacin group (n = 26), the doxazosin group (n = 26), or the combination group (n = 29). RESULTS: The average baseline NIH Chronic Prostatitis Symptom Index total scores were 22.6, 22.4, and 24.1, respectively. At 6 weeks, the total scores were 11.2 (response rate 50.3%), 17.7 (response rate 21.1%), and 13.1 (response rate 45.6%), respectively. The levofloxacin group showed a higher response rate than the doxazosin group, not at 2 weeks but at 6 weeks (p < 0.001). CONCLUSIONS: For a 6-week short-term treatment levofloxacin is more effective than doxazosin for chronic prostatitis/chronic pelvic pain syndrome. In addition, levofloxacin monotherapy was also more effective when compared with the combination therapy. | en |
dc.language.iso | en | en |
dc.publisher | Karger | en |
dc.subject | Adrenergic alpha-Antagonists/*therapeutic use | en |
dc.subject | Adult | en |
dc.subject | Anti-Bacterial Agents/*therapeutic use | en |
dc.subject | Doxazosin/*therapeutic use | en |
dc.subject | Drug Therapy, Combination | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Ofloxacin/*therapeutic use | en |
dc.subject | Prospective Studies | en |
dc.subject | Prostatitis/*drug therapy | en |
dc.title | Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 정창욱 | - |
dc.contributor.AlternativeAuthor | 임대정 | - |
dc.contributor.AlternativeAuthor | 손환철 | - |
dc.contributor.AlternativeAuthor | 이상은 | - |
dc.contributor.AlternativeAuthor | 정현 | - |
dc.identifier.doi | 10.1159/000112606 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.